Published • loading... • Updated
MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
The 150-patient trial found QA102 cut drusen volume and slowed geographic atrophy measures, while showing an acceptable safety profile.
- On Tuesday, May 5, 2026, MingMed Biotechnology announced positive Phase II results for QA102 at the ARVO annual meeting in Denver, Colorado, marking the first efficacy signals in intermediate dry age-related macular degeneration.
- Intermediate AMD represents the most prevalent stage of the disease yet remains an area of significant unmet medical need with a lack of therapies to slow or prevent progression, affecting nearly 7% of individuals over 65 years old.
- In the 150-subject Phase 2 study, the 400 mg group showed a 59.2% reduction in drusen volume and a 42.7% reduction in GA area growth after 12-month treatment relative to placebo.
- Principal investigator Sunil Patel said the Phase II data are "very encouraging for millions of people affected by intermediate or advanced forms of dry age related macular degeneration." The results demonstrate QA102's potential to address this critical need.
- Chief Technology Officer Fred Ouyang stated MingMed Biotechnology looks forward to advancing QA102 into the next Phase of clinical development, with the pipeline also including the TCM candidate QA108.
Insights by Ground AI
20 Articles
20 Articles
Aspen Daily News+19 Reposted by 19 other sources
MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
GUANGZHOU, China, May 5, 2026 /PRNewswire/ -- MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II clinical trial of QA102 in patients…
Coverage Details
Total News Sources20
Leaning Left1Leaning Right1Center14Last UpdatedBias Distribution88% Center
Bias Distribution
- 88% of the sources are Center
88% Center
C 88%
Factuality
To view factuality data please Upgrade to Premium
